ArticleFrontiers in pharmacology2022

Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage.

Wen Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.